New patent approval in Hong Kong for Episurf Medical
The Intellectual Property Department (IPD) of Hong Kong has granted another patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Design method of a rig”, is within the area of surgical instruments with a focus on the drill guide for Episurf Medical’s Episealer® Femoral Twin implant.
"This patent relates to patient-specific surgical guide instruments, forming a crucial part of the company’s Episealer® technology”, comments Katarina Flodström, COO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:45 CEST on 20 April 2022.
Tags: